Key Coverage Facts An estimated 97+ million Americans are enrolled in plans that exclude Zepbound following major PBM (pharmacy benefit manager) formulary removals [1] Only 19% of large employer plans (200+ workers) cover GLP-1 medications for weight loss (KFF 2025)rising to 43% among the largest employers (5,000+ workers, Mercer 2024) [2] [14] More than 88% of patients with coverage face prior authorization or other restrictionsyour doctor must get approval before you can fill it [1] Medicare Part D excludes weight loss drugs by federal statute (may cover for sleep apnea indication) 13 state Medicaid programs explicitly cover GLP-1s for obesity, with policies evolvingthe CMS BALANCE model may expand access starting May 2026 [9] Coverage by Plan Type If Denied, Appeals Often Succeed Over 65% of prior authorization appeals succeed when patients appealyet only about 1 in 10 patients ever file an appeal
With the results of the FLOW trial anticipated next year, as well as high rates of obesity and CVD in type 1 diabetes, there remains an unmet need for additional mechanistic and CVD/kidney outcome studies of GLP1-RAs in the population with type 1 diabetes and CKD [50]
Some people fine-tune: e.g., a patient might feel best on 1.7 mg Wegovy and not go to 2.4 because 1.7 mg curbs appetite adequately with tolerable side effects and 2.4 mg adds too much nausea
However, if the powder looks yellow, brown, or has visible moisture (clumpy or wet-looking), there may be a quality issue
Why did the TGA restrict access to BPC-157
